Connect Biopharma Hldgs analyst ratings
Connect Biopharma Hldgs analyst ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 06/02/2022 | 562.87% | Cantor Fitzgerald | → $5 | Initiates Coverage On | → Overweight |
| 05/05/2022 | 98.86% | Piper Sandler | $25 → $1.5 | Downgrades | Overweight → Neutral |
| 05/04/2022 | 1093.16% | SVB Leerink | $22 → $9 | Maintains | Outperform |
| 01/06/2022 | 2816.61% | SVB Leerink | $32 → $22 | Maintains | Outperform |
| 07/02/2021 | 3479.48% | CICC | → $27 | Initiates Coverage On | → Outperform |
| 04/13/2021 | 3479.48% | Jefferies | → $27 | Initiates Coverage On | → Buy |
| 04/13/2021 | 4142.34% | SVB Leerink | → $32 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 06/02/2022 | 562.87% | 康託·菲茨傑拉德 | → $5 | 開始承保 | →超重 |
| 05/05/2022 | 98.86% | 派珀·桑德勒 | $25 → $1.5 | 評級下調 | 超重→中性 |
| 05/04/2022 | 1093.16% | SVB Leerink | $22 → $9 | 維護 | 跑贏大盤 |
| 01/06/2022 | 2816.61% | SVB Leerink | $32 → $22 | 維護 | 跑贏大盤 |
| 07/02/2021 | 3479.48% | 中金公司 | → $27 | 開始承保 | →跑贏大盤 |
| 04/13/2021 | 3479.48% | 傑富瑞 | → $27 | 開始承保 | →購買 |
| 04/13/2021 | 4142.34% | SVB Leerink | → $32 | 開始承保 | →跑贏大盤 |
Connect Biopharma Hldgs Questions & Answers
康乃德生物Hldgs問答
The latest price target for Connect Biopharma Hldgs (NASDAQ: CNTB) was reported by Cantor Fitzgerald on June 2, 2022. The analyst firm set a price target for $5.00 expecting CNTB to rise to within 12 months (a possible 562.87% upside). 5 analyst firms have reported ratings in the last year.
坎託·菲茨傑拉德於2022年6月2日報道了康乃德生物(納斯達克代碼：CNTB)的最新目標價。這家分析公司將目標價定為5美元，預計CNTB將在12個月內上漲至(可能上漲562.87%)。去年有5家分析公司公佈了評級。
The latest analyst rating for Connect Biopharma Hldgs (NASDAQ: CNTB) was provided by Cantor Fitzgerald, and Connect Biopharma Hldgs initiated their overweight rating.
分析師對康乃德生物(納斯達克代碼：CNTB)的最新評級是由坎託·菲茨傑拉德提供的，康乃德生物Hldgs啟動了其增持評級。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Connect Biopharma Hldgs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Connect Biopharma Hldgs was filed on June 2, 2022 so you should expect the next rating to be made available sometime around June 2, 2023.
分析師們在進行了廣泛的研究後才得出股票評級，其中包括查閲公開的財務報表，與康乃德生物的高管和客户交談，以及收聽財報電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。康乃德生物Hldgs的上一次評級是在2022年6月2日提交的，因此你應該預計下一次評級將在2023年6月2日左右公佈。
While ratings are subjective and will change, the latest Connect Biopharma Hldgs (CNTB) rating was a initiated with a price target of $0.00 to $5.00. The current price Connect Biopharma Hldgs (CNTB) is trading at is $0.75, which is within the analyst's predicted range.
雖然評級是主觀的，會發生變化，但最新的康乃德生物Hldgs評級是以0.00美元至5.00美元的目標價啟動的。康乃德生物目前的交易價格為0.75美元，在分析師的預測區間內。